Cabaletta Bio, Inc. Made Headway
Cabaletta Bio, Inc. (CABA:NASDAQ) rocketted at $1.81, representing a gain of 39.2%. On Thu, May 15, 2025, CABA:NASDAQ hit a New 2-Week High of $1.81. The stock got featured on our News Catalysts scanner on Thu, May 15, 2025 at 08:46 AM in the 'BIOTECH' category. From Thu, May 01, 2025, the stock recorded 60.00% Up Days and 54.55% Green Days
The stock spiked on Mon, Dec 02, 2024 at $5.46 with a volume of 20M+.
About Cabaletta Bio, Inc. (CABA:NASDAQ)
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its technology uses chimeric autoantibody receptor T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies while sparing normal B cells. The firm offers preclinical development for the treatment of muscle-specific kinase myasthenia gravis, mucocutaneous PV, and Hemophilia A with factor VIII, or FVIII, alloantibodies. Its products comprise of DSG3/1-CAART, MuSK-CAART, and FVIII-CAART. The firm's initial focus is on Pemphigus Vulgaris, which is an autoimmune blistering skin disease.
Top 10 Gainers:
- Click Holdings Limited (CLIK:NASDAQ), 153.5%
- Aytu BioPharma, Inc. (AYTU:NASDAQ), 91.85%
- Hempacco Co., Inc. (HPCO:NASDAQ), 87.5%
- Foot Locker, Inc. (FL:NYSE), 85.7%
- Kindly MD, Inc. (KDLY:NASDAQ), 81.18%
- NuCana plc (NCNA:NASDAQ), 54.34%
- Graphjet Technology (GTI:NASDAQ), 51.55%
- Asset Entities Inc. (ASST:NASDAQ), 46.17%
- Gryphon Digital Mining, Inc. (GRYP:NASDAQ), 42.46%
- Cabaletta Bio, Inc. (CABA:NASDAQ), 39.23%